You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Chronic Leukemias

  • Authors: Michael J. Mauro, MD; Jerald Radich, MD; Hagop M. Kantarjian, MD; Nitin Jain, MD; Anthony R. Mato, MD, MSCE; Shilpa Paul, PharmD, BCOP; Courtney D. DiNardo, MD, MSCE
  • CME / ABIM MOC / CE Released: 3/2/2023
  • Valid for credit through: 3/2/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

    Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)

    IPCE - 1.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), benign hematologic diseases, and other related conditions.

The goal of this activity is that learners will be better able to personalize treatment for patients with chronic leukemias in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical trial data on treatment strategies for chronic leukemias in the frontline or R/R settings
  • Have greater competence related to
    • Selecting evidence-based treatment for patients with chronic leukemias in the frontline and R/R disease
    • Mitigating adverse events associated with current therapies for patients with chronic leukemias
  • Demonstrate greater confidence in their ability to
    • Personalize treatment for patients with chronic leukemias in an interprofessional team-based environment


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Michael J. Mauro, MD

    Leader, Myeloproliferative Neoplasms Program
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Michael J. Mauro, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Bristol Myers Squibb Company; Novartis; Pfizer, Inc.; Takeda
    Research funding from: Bristol Myers Squibb Company; Novartis; SPARC; Sun Pharmaceutical Industries, Ltd.; Takeda

  • Jerald Radich, MD

    Professor
    Clinical Research Division
    Kurt Enslein Endowed Chair
    Fred Hutchinson Cancer Center
    Seattle, Washington

    Disclosures

    Jerald Radich, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Amgen, Inc.; Cepheid; HTG Therapeutics; Novartis; NuProbe USA Inc.

  • Hagop M. Kantarjian, MD

    Professor and Chair 
    Department of Leukemia
    Samsung Distinguished University Chair in Cancer Medicine
    University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Hagop M. Kantarjian, MD, has no relevant financial relationships.

  • Nitin Jain, MD

    Associate Professor of Medicine
    Department of Leukemia
    University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Nitin Jain, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie, Inc.; Adaptive Biotechnologies; AstraZeneca Pharmaceuticals, LP; BeiGene (Beijing) Co., Ltd.; Bristol Myers Squibb Company; CareDX; Cellectis; Genentech; Gilead Sciences, Inc.; Ipsen; Janssen; Kite Pharma, Inc.; MEI Pharma, Inc.; Pharmacyclics, Inc.; Precision Biosciences; TG Therapeutics, Inc.
    Research funding from: AbbVie, Inc.; Adaptive Biotechnologies; ADC Therapeutics; Aprea Therapeutics; AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Cellectis; Dialectic Therapeutics; Fate Therapeutics, Inc.; Genentech; Gilead Sciences, Inc.; Incyte Corporation; Kite Pharma, Inc.; Loxo Oncology; Medisix Therapeutics Pte. Ltd.; Mingsight Pharmaceuticals Inc; Newave Pharmaceuticals Inc.; NovalGen; Pfizer, Inc.; Pharmacyclics, Inc.; Precision Biosciences; Servier; Takeda; TransThera Biosciences Co. Ltd.
    Contracted researcher for: AbbVie, Inc.; Adaptive Biotechnologies; ADC Therapeutics; Aprea Therapeutics; AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Cellectis; Dialectic therapeutics; Fate Therapeutics, Inc.; Genentech; Gilead Sciences, Inc.; Incyte Corporation; Kite Pharma, Inc.; Loxo Oncology; Medisix Therapeutics Pte. Ltd.; Mingsight Pharmaceuticals Inc.; Newave Pharmaceuticals Inc.; NovalGen; Pfizer, Inc.; Pharmacyclics, inc.; Precision Biosciences; Servier; Takeda; TransThera Biosciences Co. Lt.

  • Anthony R. Mato, MD, MSCE

    Director, CLL Program
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Anthony R. Mato, MD, MSCE, has no relevant financial relationships.

  • Shilpa Paul, PharmD, BCOP

    Clinical Pharmacy Specialist - Leukemia
    University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Shilpa Paul, PharmD, BCOP, has the following relevant financial relationships: 
    Consultant or advisor for: Amgen, Inc.; Novartis

  • Courtney D. DiNardo, MD, MSCE

    Associate Professor
    Department of Leukemia
    Division of Cancer Medicine
    University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Courtney D. DiNardo, MD, MSCE, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie, Inc.; Agios Pharmaceuticals; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Genentech; Genmab; Novartis; Notable Labs; Servier; Takeda
    Research funding from: AbbVie, Inc.; Agios Pharmaceuticals; Astex Pharmaceuticals; Bristol Myers Squibb Company; Calithera Biosciences; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Loxo Oncology

Editor

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this live activity for a maximum of 1.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number JA0007105-0000-23-102-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Chronic Leukemias

Authors: Michael J. Mauro, MD; Jerald Radich, MD; Hagop M. Kantarjian, MD; Nitin Jain, MD; Anthony R. Mato, MD, MSCE; Shilpa Paul, PharmD, BCOP; Courtney D. DiNardo, MD, MSCEFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/2/2023

Valid for credit through: 3/2/2024, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate (PRO)

Dr Mauro discusses the advantages of TFR as the goal of frontline treatment for chronic myeloid leukemia (CML).
Michael J. Mauro, MD

Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate (CON)

Dr Radich explores the drawbacks of aiming for TFR as the goal of frontline CML treatment.
Jerald Radich, MD

Sequencing Treatments in Relapsed/Refractory CML

Dr Kantarjian shares his insights for effectively sequencing tyrosine kinase inhibitors in R/R CML.
Hagop M. Kantarjian, MD

Frontline CLL Management: Chemoimmunotherapy vs BTK Inhibitors

Dr Jain updates us on recent advances in the frontline management of chronic lymphocytic leukemia (CLL).
Nitin Jain, MD

Management of Relapsed/Refractory CLL

Dr Mato reviews the current and emerging management options for R/R CLL.
Anthony R. Mato, MD, MSCE

Managing Oral Medications in Chronic Leukemias

Dr Paul explores best practices for selecting and managing oral therapies for chronic leukemias.
Shilpa Paul, PharmD, BCOP
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print